Know Cancer

or
forgot password

Observational, Post-authorization, Cross-sectional Study to Evaluate the Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma


N/A
18 Years
N/A
Not Enrolling
Both
Diffuse Large B-cell Lymphoma

Thank you

Trial Information

Observational, Post-authorization, Cross-sectional Study to Evaluate the Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma


The main aim of this study is to compare the prognostic value of R-IPI at diagnosis and
relapse, relating it with the obtained response after second line

Inclusion Criteria


- Age 18 > years old

- Patients with refractory/relapsed diffuse large B-cell lymphoma after first line
treatment with rituximab, with or without transplantation. Patients must have
finished a rescue treatment including rituximab

- Ability to understand and willingness to sign a written informed consent

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Cross-Sectional

Outcome Measure:

R-IPI Index

Outcome Description:

Data will be recorded from diagnosis to second line response, an expected average of 7 months

Outcome Time Frame:

Average of 7 months

Safety Issue:

No

Principal Investigator

Carlos Panizo, PhD

Investigator Role:

Study Chair

Investigator Affiliation:

Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea

Authority:

Spain: Spanish Agency of Medicines

Study ID:

PRO-R-IPI

NCT ID:

NCT01369784

Start Date:

February 2009

Completion Date:

March 2011

Related Keywords:

  • Diffuse Large B-Cell Lymphoma
  • Diffuse large B-cell Lymphoma
  • R-IPI
  • Lymphoma
  • Lymphoma, B-Cell
  • Lymphoma, Large B-Cell, Diffuse

Name

Location